ISPD 2021辩论:所有体外受精周期是否都应进行植入前遗传学检测以改善胎儿健康与妊娠结局
本文为ISPD 2021辩论稿,讨论所有体外受精(IVF)周期是否应常规进行植入前遗传学检测(PGT)。辩论前投票显示64%反对对所有IVF周期进行PGT,主要顾虑为费用、知情同意和「滑坡效应」。尽管辩论者讨论了患者与提供者的意愿及对未出生孩子的伦理担忧,听众未被说服,三分之二仍反对对所有IVF周期进行PGT。
要点
- 辩论前投票64%反对对所有IVF周期进行PGT,听众最终三分之二仍反对。
- 反对顾虑包括费用、知情同意和「滑坡效应」。
- PGT-A改善IVF结局的证据不一致,无论以流产或活产衡量。
核心结论
- 辩论前64%反对对所有IVF周期进行PGT,辩论后听众三分之二仍反对。
研究设计与样本
- ISPD 2021辩论,包含辩论前投票和辩论后听众投票。
主要发现
- 辩论前投票显示64%反对对所有IVF周期进行PGT。
- 辩论后听众三分之二仍反对对所有IVF周期进行PGT。
- PGT-A改善IVF结局的证据不一致,无论以流产或活产衡量。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
For 3 decades, couples at increased risk for a genetic disorder have been offered preimplantation genetic testing (PGT). Simultaneously, PGT for aneuploidy (PGT-A) to improve in vitro fertilization (IVF) outcomes was introduced, but evidence of value-added remains inconsistent. Recently, lower genetic testing costs and shorter turnaround time have reinvigorated PGT-A. Additionally, a shift from blastomere (day 3) to blastocyst (day 5) transfer and embryo freezing advances support PGT without the time constraints of immediate transfer. PGT-A transformed from a time-constrained analysis of 1-2 cells to an "add on" study for all IVF. But should it be offered to all IVF patients? And if not, under what conditions? Pre-debate polling found 64% opposed to PGT for all IVF cycles with concerns voiced about cost, informed consent, and a "slippery slope". Leaving aside the inconsistent evidence of IVF improvement whether measured as miscarriage or livebirths with PGT-A, the debaters grappled with patient and provider desires versus the ethical concerns for the unborn child. However, the audience was not swayed; two thirds remained opposed to PGT for all IVF cycles.
引用
- Wilkins-Haug L, Amor DJ, Savulescu J, et al. ISPD 2021 debate - All in vitro fertilization cycles should involve pre-implantation genetic testing to improve fetal health and pregnancy outcomes. Prenat Diagn. 2022. PMID: 35470429. doi:10.1002/pd.6156
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。